inter-alpha-trypsin inhibitor heavy chain family member 6Genealiases: ITIH5L · UNQ6369 · dJ14O9.1
Q-omics provides the consensus-scored ITIH6 profile across patient tissues and cancer cell-line models. ITIH6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ITIH6 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, ITIH6 RNA expression shows 13,717 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, BLCA, and THYM as cancer lineages where ITIH6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITIH6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITIH6 survival associations across molecular data types. ITIH6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITIH6 RNA expression–survival associations across cancer types. High ITIH6 expression shows unfavorable associations in UVM, KIRC, COAD, LGG and ACC, but favorable associations in SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ITIH6 RNA expression.
This table summarizes ITIH6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ITIH6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITIH6 shows higher tumor expression in BLCA, COAD, BRCA, LUSC, STAD and LUAD. The BLCA box plot shows higher ITIH6 RNA expression in tumor versus normal tissue (log2 FC = +0.320, t-test p < 0.001).
This table shows molecular features associated with ITIH6 in patient tissues and cancer cell lines. In patient samples, ITIH6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ITIH6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and SKIN.
